Patients with a hereditary form of emphysema caused by alpha-1 proteinase inhibitor (A1PI) deficiency now have another therapeutic option. The FDA recently approved alpha1-proteinase inhibitor (human) [Aralast, Baxter] for chronic augmentation therapy in patients having congenital deficiency of A1PI with clinically evident emphysema. Aralast is currently available exclusively through the specialty pharmacy providers Accredo Health, Caremark, and Coram Healthcare. To obtain more information about Aralast, contact Baxter at (800) 423-2090.
Patient Outcomes, Holistic Care Hinges on Evolving Role of Pharmacist | Asembia 2025
Published: April 29th 2025 | Updated: April 29th 2025From medication dispensers to comprehensive patient care advocates, pharmacists have never been more essential to the health care team and to patients in specialty care.